Zevra Therapeutics, Inc., was incorporated in Iowa in October 2006 and reorganized in Delaware in May 2014. The company is a rare disease company that combines science, data and patient needs to create translational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapies to people with rare diseases. With a unique, data-driven development and commercialization strategy, the company is overcoming complex drug development challenges to deliver new therapies to the rare disease community. The company has a diverse product portfolio and product candidates that include preclinical development programs, clinical-stage pipelines and commercial-stage assets. The company's team has expertise and a successful track record of advancing promising therapies that face complex clinical and regulatory challenges by balancing science and data with patient needs. 

Zevra Therapeutics to present at investor conferences in September. The company's executive leadership team will participate in fireside chats at Cantor Global Healthcare Conference, Morgan Stanley 24th Annual Global Healthcare Conference, and H.C. Wainwright 28th Annual Global Investment Conference. The presentations will take place on September 9, 14, and 15, 2026, respectively. Zevra Therapeutics is a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases.

Zevra

Zevra Therapeutics to Present at Investor Conferences

Zevra Therapeutics will present long-term MIPLYFFA data in Niemann-Pick disease at the 2026 SSIEM Annual Symposium. The data shows sustained disease stabilization across diverse patient populations, with treatment experience extending up to eight years and a consistent long-term safety profile. ZVRA has traded between $7.16 and $15.03 over the past year.

Zevra to Present Long-Term Data on Miplyffa in Niemann-Pick Disease at SSIEM 2026

Zevra Therapeutics presented two posters at the SSIEM Annual Symposium featuring long-term real-world data on MIPLYFFA for Niemann-Pick disease type C treatment. The presentations highlight sustained disease stabilization across a broad range of patients, including adults, with up to eight years of real-world treatment experience. Key data highlights include durable disease stabilization through four years, consistent stabilization across age groups, and sustained stabilization in children.

Zevra Therapeutics Presents Long-Term Real-World Data on MIPLYFFA for NPC Treatment

Zevra Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4)

Zevra Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4)

According to Zevra's 15-minute chart, the Moving Average Convergence Divergence (MACD) and Kinetick Daily Oscillator (KDJ) indicators have both triggered death crosses, as of August 20, 2026 at 09:45. This indicates that the stock price is likely to continue its downward trajectory, with momentum shifting in favor of a further decrease.As of August 20, 2026 at 09:45, Zevra Therapeutics' 15-minute chart indicates that both the Moving Average Convergence Divergence (MACD) and Kinetick Daily Oscillator (KDJ) have triggered death crosses. A death cross occurs when a short-term moving average crosses below a long-term moving average, <a href="https://www.investopedia.com/terms/d/deathcross.asp">signaling a potential bearish trend</a>. In this case, the pattern suggests that the stock price may continue its downward trajectory, with momentum shifting in favor of further declines.While the death cross is often interpreted as a bearish signal, historical data shows that it does not always lead to severe market downturns. In fact, market history suggests that the death cross has often been followed by <a href="https://www.investopedia.com/terms/d/deathcross.asp">short-term rebounds with above-average returns</a>. For example, the S&amp;P 500 has historically shown gains in the months following a death cross, <a href="https://www.investopedia.com/terms/d/deathcross.asp">averaging around 6.3% over</a> a one-year period.Investors should be cautious when interpreting the death cross as a definitive predictor of market performance. It is more accurately viewed as <a href="https://www.investopedia.com/terms/d/deathcross.asp">a coincident indicator of market weakness</a> rather than a leading one. As such, it should be used in conjunction with other analytical tools and market fundamentals to make informed investment decisions.

ZVRA News